Tuoxin Pharmaceutical Group (301089.SZ) has forecasted a pre-tax loss, anticipating a net loss of 15-21 million yuan for the year 2024, turning from profit to loss.

21/01/2025

GMT Eight

Tuoxin Pharmaceutical Group (301089.SZ) released the 2024 annual performance forecast, and the company expects a net loss attributable to shareholders of the listed company in 2024 of 15-21 million yuan, turning from profit to loss; deducting non-recurring gains and losses, the net loss is expected to be 22.6-28.6 million yuan, also turning from profit to loss.

PKU HealthCare Corp., (000788.SZ) is expected to see a net profit of 115 million to 145 million in 2024, an increase of 159.26% to 226.90%.

Pansoft (300996.SZ) has issued a profit increase forecast, with an expected annual net profit of 1.12 billion to 1.4 billion yuan, representing a year-on-year growth of 80.18% to 125.22%

Contact: contact@gmteight.com

Tuoxin Pharmaceutical Group (301089.SZ) has forecasted a pre-tax loss, anticipating a net loss of 15-21 million yuan for the year 2024, turning from profit to loss.

RECOMMEND

SWIRE PACIFIC A (00019) spent approximately HKD 10 million to repurchase 146,000 shares on January 22nd.

Liaoning Fu-An Heavy Industry (603315.SH) expects a net profit of 85 million to 95 million yuan for the year 2024, an increase of 18.38% to 32.30% compared to the previous year.

Shengda Resources (000603.SZ) has released a pre-increase announcement, with a projected net profit for the year 2024 expected to be between 350 million to 400 million yuan, an increase of 136.51% to 170.29%.